(Editor's Note: This Columnist Conversation post originally ran on RealMoney.com at 7:08 a.m. EDT. If you would like to subscribe to RealMoney, please click here.)
CHICAGO -- My weekend at the American Society of Clinical Oncology (ASCO) annual meeting was almost totally occupied by ImClone (IMCL Quote)-related work, which gave me very little time to devote to any other company news. I apologize for that, but it was impossible to find the time to really dig into other stories.
RealMoney readers can check the Columnist Conversation archives for my weekend postings. Obviously, there were non-ImClone happenings at ASCO this year (although to be honest, not much). Here are pocket sketch observations of some other possible stock-moving news:
Amgen (AMGN Quote): Denosumab looks like it will have a role in the cancer market, based on data presented this weekend. The big opportunity for the experimental drug is in osteoporosis, and that's where most investors are focused, but "D-Mab" could also be used to treat bone-related side effects of cancer treatments. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet